320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
- Disease/Condition
- Atrial Fibrillation
- Drug/Device/Intervention
- CT
- Study type
- Interventional
- Intervention type
- diagnostic test
- Primary sponsor
- Johns Hopkins University
- Phase
- N/A
- Start date
- Jun 01, 2024
- End date
- Apr 01, 2025
- Enrollment
- 100 participants
Recurrence of Atrial Fibrillation,Occurrence of ER visits, hospitalizations for cardiovascular causes
This study explores the relationship between myocardial fibrosis and patient outcomes in
 Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an
 accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of
 fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF
 recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make
 ECV a key factor in deciding AF treatment strategies.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06308094
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06308094 through Pure Global AI's free database. This phase not specified trial is sponsored by Johns Hopkins University and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.